American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 902-911 , November 2009

Association of LDL Cholesterol and Inflammation With Cardiovascular Events and Mortality in Hemodialysis Patients With Type 2 Diabetes Mellitus

  • Vera Krane, MD

      Affiliations

    • Department of Medicine I, Division of Nephrology, University of Würzburg, Germany
    • Corresponding Author InformationAddress correspondence to Vera Krane, MD, University of Würzburg, Department of Medicine, Division of Nephrology, University Hospital, Josef-Schneider-Str 2, D-97080 Würzburg, Germany
    • ,
  • Karl Winkler, MD

      Affiliations

    • Department of Medicine, Division of Clinical Chemistry, University Medical Center Freiburg, Freiburg, Germany
    • ,
  • Christiane Drechsler, MD

      Affiliations

    • Department of Medicine I, Division of Nephrology, University of Würzburg, Germany
    • ,
  • Jürgen Lilienthal

      Affiliations

    • DATAMAP GmbH, Freiburg, Germany
    • ,
  • Winfried März, MD

      Affiliations

    • Synlab Center of Laboratory Diagnostics, Heidelberg, Germany
    • ,
  • Christoph Wanner, MD

      Affiliations

    • Department of Medicine I, Division of Nephrology, University of Würzburg, Germany
    • ,
  • German Diabetes and Dialysis Study Investigators

Received 15 September 2008 ,Accepted 15 June 2009.

References 

  1. Ridker PM, Glynn RJ, Hennekens CH. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011
  2. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  3. Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int. 2008;74:1461–1467
  4. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA. 2004;291:451–459
  5. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  6. Wanner C, Krane V, Ruf G, Marz W, Ritz E. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis (Die Deutsche Diabetes Dialyse Studie Investigators). Kidney Int Suppl. 1999;71:S222–S226
  7. Wanner C, Krane V, Marz W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D Study): Demographic and baseline characteristics. Kidney Blood Press Res. 2004;27:259–266
  8. Krane V, Heinrich F, Meesmann M, et al. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clin J Am Soc Nephrol. 2009;4:394–400
  9. Nauck M, Winkler K, Marz W, Wieland H. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem. 1995;41:1761–1767
  10. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303:276–282
  11. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444
  12. Chiang CK, Ho TI, Hsu SP, et al. Low-density lipoprotein cholesterol: Association with mortality and hospitalization in hemodialysis patients. Blood Purif. 2005;23:134–140
  13. Coresh J, Longenecker JC, Miller ER, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl 12):S24–S30
  14. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887–1893
  15. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–482
  16. Gierens H, Nauck M, Roth M, et al. Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. Arterioscler Thromb Vasc Biol. 2000;20:1777–1783
  17. Amarenco P, Goldstein LB, Callahan A, et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009;204:515–520
  18. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–1839
  19. Patel A, Woodward M, Campbell DJ, et al. Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. Eur Heart J. 2005;26:1910–1915
  20. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med. 1989;320:904–910
  21. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: The Copenhagen City Heart Study. BMJ. 1994;309:11–15
  22. Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol. 2000;36:1774–1780
  23. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: Effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol. 2007;18:304–311
  24. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236
  25. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42:1050–1065

 Originally published online as doi: 10.1053/j.ajkd.2009.06.029 on September 27, 2009.

 A list of the German Diabetes and Dialysis Study Investigators is available at www.nephrologie.uni-wuerzburg.de/4D/index_4d.htm.

PII: S0272-6386(09)00969-X

doi: 10.1053/j.ajkd.2009.06.029

American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 902-911 , November 2009

Article Tools

* Image Usage & Resolution